Maintenance therapy for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether a combination of two targeted drugs can help keep extensive-stage small cell lung cancer from growing after initial treatment. The goal is to see if this maintenance approach extends the time before the cancer worsens.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have been diagnosed with extensive-stage small cell lung cancer.
- You have finished first-line chemotherapy and/or immunotherapy, and your cancer has not progressed.
- You have at least one measurable tumor that hasn't been treated with radiation recently.
- You are generally able to care for yourself (ECOG 0-1).
- Your blood counts and organ function are within the required ranges.
- If you have brain metastases, they must be stable and not require immediate treatment.
- You have not had prior treatment with certain immune checkpoint inhibitors or targeted therapies for your lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new maintenance therapy (adebrelimab plus apatinib) for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy and immunotherapy. The goal is to help keep the cancer from coming back longer.
This trial tests a combination of drugs as a maintenance therapy after initial chemotherapy for extensive-stage small cell lung cancer. It aims to see if this combination can help keep the cancer from growing.
This study tests a combination of two chemotherapy drugs (irinotecan liposome and a platinum drug) plus an immunotherapy drug and a targeted therapy (anlotinib) as maintenance treatment after initial chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination keeps the cancer from growing for as long as possible.
This trial is testing whether a maintenance therapy using anlotinib (a drug that blocks blood vessel growth) combined with immunotherapy can help keep extensive-stage small cell lung cancer from progressing after initial chemoimmunotherapy. It aims to see if this reduces the chance of the cancer coming back and improves survival.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Hear when a new Maintenance Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.